Login to Your Account

Bydureon's Leg Up

Ipsen/Roche Ca-'taspo'-phe Boosts GLP-1 Bid for Amylin

By Randy Osborne

Monday, June 21, 2010
A year-long (at least) delay of taspoglutide, the Phase III diabetes candidate from Ipsen SA and Roche AG, provides a welcome lift for Amylin Pharmaceuticals Inc.'s would-be competitor Bydureon, though the hypersensitivity reactions holding up the former once-weekly glucagon-like peptide-1 analogue could cast some doubt on the class to which Bydureon also belongs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription